Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

0.6752 +0.0182 (+2.77%)
Official Closing Price Updated: 8:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics: Q3 Earnings Insights
Via Benzinga
Earnings Preview: Lineage Cell Therapeutics
Via Benzinga
Lineage Cell Therapeutics Earnings Preview
Via Benzinga
Lineage Cell Therapeutics: Q1 Earnings Insights
Via Benzinga
Lineage Cell Therapeutics, Longeveron And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 25 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
3 Penny Stocks to Buy for the Next Bull Run
While penny stocks to buy represent a terribly risky venture, it’s possible that maybe one of these ideas could skyrocket. 
Via InvestorPlace
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Here are the best longevity stocks to consider. Each stock listed comes with their unique reasons to buy them. 
Via InvestorPlace
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
Lineage Cell Therapeutics Inc (NYSE: LCTX) has initiated certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the company’s exclusive option and... 
Via Benzinga
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Why DLocal Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Lineage Cell Therapeutics' Lung Cancer Vaccine: Initial Data Reveals Modest, Durable Immune Response
Lineage Cell Therapeutics Inc (NYSE: LCTX) and Cancer Research UK revealed primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small  
Via Benzinga
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)
From Lineage Cell Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback